Article Figures & Tables
Tables
- Table 1
Effects of 4 monoamine oxidase (MAO) inhibitors on performance of mice in the forced swimming test
Dose, mg/kg MAO inhibitor; mean period of immobility (and SEM), s, and % of zero dose Tranylcypromine 4-Fluorotranylcypromine Phenelzine N2-Acetylphenelzine 0.0 231 (3) 100 233 (2) 100 222 (5) 100 232 (3) 100 0.5 204 (8) 88 228 (3) 98 ND ND 1.0 223 (4) 97 226 (3) 97 227 (4) 102 237 (1) 102 2.0 214 (12) 93 208 (17) 89 223 (5) 100 220 (10) 95 4.0 191 (15)* 83 196 (23) 84 232 (3) 104 226 (5) 97 8.0 170 (15)† 74 192 (13) 82 235 (2) 106 228 (4) 98 16.0 ND ND 224 (6) 101 228 (4) 98 32.0 ND ND 231 (4) 104 212 (7)‡ 91 p value§ 0.002 0.104 0.250 0.050 MAO inhibitor; dose, mg/kg Treatment; mean period of immobility (and SEM), s % change† p value‡ Single drug* Interaction (clonidine + MAO inhibitor) TCP < 0.001 0.0 188 (21) NA NA 0.5 204 (12) 163§ (19) −17 2.0 214 (12) 133§¶ (25) −35 8.0 170§ (15) 102§ (25) −30 FTCP < 0.001 0.0 230 (2) NA NA 0.5 228 (3) 191¶ (6) −16 2.0 208 (17) 173§¶ (11) −15 8.0 191 (13) 129§¶ (22) −27 PLZ < 0.001 0.0 214 (6) NA NA 2.0 223 (5) 170 (22) −23 8.0 235 (2) 143§¶ (21) −42 32.0 231 (3) 170¶ (13) −27 AcPLZ < 0.001 0.0 214 (6) NA NA 2.0 219 (10) 155§¶ (20) −27 8.0 228 (4) 182 (11) −20 32.0 211 (7) 111§¶ (26) −43 Note: TCP = tranylcypromine, FTCP = 4-fluorotranylcypromine, PLZ = phenelzine, AcPLZ = N2-acetylphenelzine, NA = not applicable.
↵* For zero doses of the 4 MAO inhibitors, the data are for clonidine alone (0.06 mg/kg).
↵† Calculated as (% interaction – % MAO inhibitor alone), where the percentages are calculated with respect to mean periods of immobility (and SEM) for control (vehicle). Mean period of immobility (and SEM) for controls, in seconds: TCP 231 (3), FTCP 223 (2), PLZ 222 (5) and AcPLZ 232 (3).
↵‡ F-test.
↵§ Significantly different from vehicle (p < 0.01) (Sidak’s test, n = 10).
↵¶ Significantly different from MAO inhibitor alone (p < 0.01) (Sidak’s test, n = 10).
MAO inhibitor; dose, mg/kg Treatment; mean period of immobility (and SEM), s % change† Single drug* Interaction (lithium + MAO inhibitor) TCP 0.0 218 (4) NA 0.5 223 (4) 192 (7) −14 2.0 189 (6) 183 (6) −3 8.0 155‡ (14) 165‡ (15) +4 FTCP 0.0 230 (3) NA 0.5 225 (5) 206 (5) −8 2.0 220 (6) 193§ (10) −12 8.0 209 (5) 206 (8) −1 PLZ 0.0 223 (8) NA 2.0 227 (4) 224 (5) −2 8.0 228 (4) 223 (4) −2 32.0 204‡ (6) 213 (3) +4 AcPLZ 0.0 227 (3) NA 2.0 226 (2) 221 (4) −2 8.0 226 (4) 226 (3) 0 32.0 207‡ (6) 204‡ (7) −1 ↵* For zero doses of the 4 MAO inhibitors, the data are for lithium alone (1 mEq/kg).
↵† Calculated as (% interaction – % MAO inhibitor alone), where the percentages are calculated with respect to mean periods of immobility for control (vehicle). Mean period of immobility (and SEM) for controls, in seconds: TCP 216 (4), FTCP 224 (4), PLZ 228 (4), AcPLZ 231 (1).
↵‡ Significantly different from vehicle (p < 0.01) (Sidak’s test, n = 10).
↵§ Significantly different from vehicle (p < 0.05) (Sidak’s test, n = 10).
MAO inhibitor; dose, mg/kg Treatment; mean period of immobility (and SEM), s % change† Single drug* Interaction (quinine + MAO inhibitor) TCP 0.0 217 (4) NA 0.5 223 (4) 206 (5) −8 2.0 189 (6) 187 (9) −1 8.0 155‡ (14) 178‡ (10) +10 FTCP 0.0 227 (3) NA 0.5 235 (9) 221 (18) −6 2.0 236 (6) 234 (14) −1 8.0 222 (23) 216 (22) −3 PLZ 0.0 231 (3) NA 2.0 232 (2) 225 (4) −3 8.0 228 (3) 223 (4) −2 32.0 227 (4) 226 (4) 0 AcPLZ 0.0 221 (5) NA 2.0 227 (3) 194‡ (5) −15§ 8.0 221 (4) 196‡ (9) −11¶ 32.0 223 (3) 178‡ (6) −21§ ↵* For zero doses of the 4 MAO inhibitors, the data are for quinine alone (0.5 mg/kg).
↵† Calculated as (% interaction – % MAO inhibitor alone), where the percentages are calculated with respect to mean periods of immobility for control (vehicle). Mean period of immobility (and SEM) for controls, in seconds: TCP 216 (4), FTCP 231 (2), PLZ 231 (3), AcPLZ 221 (5).
↵‡ Significantly different from vehicle (p < 0.01) (Sidak’s test, n = 10).
↵§ Significantly different from AcPLZ alone (p < 0.01) (Sidak’s test, n = 10).
↵¶ Significantly different from AcPLZ alone (p < 0.05) (Sidak’s test, n = 10).